CEO since January 8, 2020
Education/experience: Martin Jönsson has a MSc in business from University of Lund, and with studies at University of Freiburg, Germany and University of Ottawa, Canada. Martin Jönsson has more than 20 years’ experience in the global pharmaceutical industry, working for Roche and Ferring Pharmaceuticals, with senior positions in several different areas. He has worked with business development, sales, marketing, alliance management and medical affairs.
Current assignment: None
Completed assignments (last five years): Senior positions in several different areas at Ferring Pharmaceuticals in the United States.
Holdings: 102,000 shares and 300,000 share options.
CSO since January 8, 2020 (CEO 2017 - January 7, 2020)
Johan Sandin is a behavioral pharmacologist within the neurology area with a large academic and industrial experience. He has 17 years of experience from drug dixcovery, including 10 years at AstraZeneca where he had several scientific, project and leadership roles with responsibility for in vitro biology, in vivo biology and biochemical biomarkers within the CNS area.
Education: Ph.D. in Neuroscience from Karolinska Institutet, Sweden.
Holdings: 850,000 shares.
Education/experience: Birgitta Lundvik has an MSc in business from Uppsala University and an eMBA in finance from Stockholm Business school, Sweden. Birgitta Lundvik has more than 25 years of experience from software development, life science and real estate companies. She has taken part in several M&A projects and has a broad experience of venture capital companies.
Current assignment: Chairman of the board of LobSor Pharmaceuticals AB. Member of the board and CEO of Enable – Finance & Business Development in Sweden AB. Secretary and Treasurer of Favro North America Inc. Deputy chairman of Swedsoft. Alternate member of the board of Helander & Lundvik Ekonomikonsulter AB, Balanced Competence Uppsala Redovisningsbyrå AB, Märsta Mur & Puts AB (unä) and Brf Arken.
Completed assignments (last five years): Member of the board and CEO of Hansoft Technologies AB. CEO of Favro AB and Nonna Holding AB.
Holdings: 65,000 shares.
Head of Discovery
Pontus Forsell has 20 years of experience from several biotech and pharmaceutical companies, such as Biolipox, Orexo, Merck and AstraZeneca in project and management positions. He is an expert in early phase drug discovery within the disease areas neurology, analgesia, as well as respiratory and inflammation.
Education: Ph.D. in Medical Biochemistry & Biophysics from Karolinska Institutet, Sweden.
Holdings: 853,643 shares.
An van Es-Johansson
Head of Development, engaged as a consultant since 2018
Education/experience: An van Es Johansson holds an M.D. (physician) from Erasmus University Rotterdam (the Netherlands). An has previously held various executive positions relating to clinical development, medical affairs, business development and marketing at Sobi, Eli Lilly, Roche, Pharmacia & Upjohn and biotechnology companies in the USA, the Netherlands, Switzerland and Sweden. She is an entrepreneur and a mentor/coach with extensive experience.
Current assignments: Member of the boards of Van Es Consulting AB, Medivir AB, BioInvent International AB, Savara Pharmaceuticals Inc, PLUS Therapeutics Inc and Agendia BV. Advisor & consultant.
Completed assignments (past five years): VP Medical Affairs at Swedish Orphan Biovitrum AB. Member of the Board of Directors for AlzeCure Pharma through March 2, 2020.
Holdings: 82,000 shares and 25,000 share options.
Holdings in AlzeCure Pharma AB as of March 31, 2020.